Drugs / Tivozanib
Tivozanib
also known as
AV-951 · tivozanib hydrochloride · KRN951 · (tivozanib hydrochloride hydrate · ASP-4130 · DC-001164TIVOZANIBAV9511-(2-CHLORO-4((6,7-DIMETHOXYQUINOLIN-4-YL)OXY)PHENYL)-3-(5-METHYLISOXAZO-3-YL)UREA · FOTIVDA · KIL-8951 · +5 more
Small molecule targets KIT, PDGFRB via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed renal cell adenocarcinoma 4 milestones | |||||
| Filed | US (FDA) | — | renal cell adenocarcinoma | 2020-03-31 | “today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib” aveooncology.com ↗ |
| Filed | EU (EMA) | — | renal cell adenocarcinoma | 2016-03-01 | “today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line treatment of advanced renal cell...” aveooncology.com ↗ |
| Rejected (CRL) | US (FDA) | — | renal cell adenocarcinoma | 2013-06-10 | “AVEO Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma” aveooncology.com ↗ |
| Filed | US (FDA) | TIVOPATH | renal cell adenocarcinoma | 2012-09-28 | “AVEO and Astellas announced that the FDA accepted for filing the NDA for tivozanib with the proposed indication for the treatment of patients with advanced RCC” aveooncology.com ↗ “In June 2020, AVEO announced that the FDA accepted for filing its NDA seeking approval for tivozanib as a treatment for relapsed or refractory RCC.” aveooncology.com ↗ “AVEO submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for tivozanib in patients with advanced RCC.” aveooncology.com ↗ “AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib” astellas.com ↗ “the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for tivozanib” astellas.com ↗ “the tivozanib New Drug Application (NDA), which was submitted by AVEO on September 28, 2012” astellas.com ↗ |
| Approved Indication not stated 2 milestones | |||||
| Approved | US (FDA) | FOTIVDA | — | 2021-03-10 | fda.gov ↗ |
| Approved | EU (EMA) | Fotivda | — | 2017-08-24 | europa.eu ↗ |
Trials 39
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT01631097 | May 2012 → Jan 2014 | — | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01363804 | May → Jul 2011 | — | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01363778 | May → Jul 2011 | — | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01316848 | Feb → May 2011 | — | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01306630 | Nov 2010 → Jan 2014 | cancer | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01210846 | Oct 2010 → Mar 2011 | cancer | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00970411 | Aug 2009 → Apr 2016 | cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00717340 | Feb 2009 → Jan 2011 | breast cancer | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00826878 | Jan 2009 → Mar 2011 | non-small cell lung carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00660153 | Jun 2008 → Jun 2012 | colorectal cancer | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00563147 | Nov 2007 → Nov 2010 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT04645160 | Mar 2022 → Dec 2028 expected | cholangiocarcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05000294 | Dec 2021 → Dec 2026 expected | bile duct cancer, breast cancer, gallbladder cancer, neuroendocrine neoplasm +5 | University of Florida | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03970616 | Sep 2019 → Apr 2023 | hepatocellular carcinoma | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03136627 | Mar → Dec 2017 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01728181 | Nov 2013 → Mar 2016 | non-small cell lung carcinoma | University of Utah | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01835223 | Jul 2013 → Dec 2018 | adult hepatocellular carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01058655 | Feb 2010 → Sep 2013 | digestive system cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 214 trials · 1 missed | ||||||
| Phase 2 | NCT07218692 | Aug 2026 → Aug 2027 | clear cell renal carcinoma, sarcomatoid renal cell carcinoma | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT06053658 | Jan 2024 → Nov 2028 expected | renal cell carcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT01972516 | Nov 2013 → Jul 2015 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01885949 | Sep 2013 → May 2024 | prostate cancer | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01853644 | Jun 2013 → Oct 2018 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT01846871 | Jun 2013 → Sep 2014 | glioblastoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01834183 | Jun 2013 | renal cell carcinoma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT01782313 | Mar 2013 → May 2015 | soft tissue sarcoma | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT01807156 | Mar 2013 → Feb 2015 | hepatocellular carcinoma | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT01745367 | Nov 2012 → Jun 2014 | triple-negative breast carcinoma | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01673386 | Jul 2012 → Jan 2014 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01478594 | Dec 2011 → Sep 2013 | colorectal cancer | AVEO Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT01297244 | Jan 2011 → Oct 2012 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00502307 | Oct 2007 → Aug 2010 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 35 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT06661720 | Mar 2025 → Nov 2037 expected | clear cell renal carcinoma, renal pelvis carcinoma | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT04987203 | Sep 2021 → Jan 2026 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 3 | NCT02627963 | May 2016 → Oct 2018 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 3 | NCT01076010 | Mar 2010 → Jul 2014 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01030783 | Dec 2009 → Jul 2012 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Completed | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT01769885 | Mar → Jun 2013 | renal cell carcinoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| — | NCT01369433 | Jun 2010 → Jun 2015 | cancer | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 82
| Date | Issuer | Release |
|---|---|---|
| 2025-06-03 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology, an LG Chem company, Presents Three Posters at ASCO 2025 Annual Meeting aveooncology.com ↗
AVEO presented data from an exploratory sub-analysis of the TiNivo-2 study, evaluating the efficacy of tivozanib as a 2 nd line treatment option in patients who failed 1 st line vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) and immune |
| 2025-02-18 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology, an LG Chem company, Presents Two Posters for Tivozanib at the 2025 ASCO GU Meeting aveooncology.com ↗
Cumulative data of three Phase 3 studies demonstrate greater exposure of tivozanib is associated with increased clinical benefit |
| 2024-09-16 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology, an LG Chem company, Present TiNivo-2 Results and TIVO-3 Exploratory Post Immunotherapy Survival Analysis at ESMO 2024 aveooncology.com ↗
Additionally, a follow up exploratory analysis from TIVO-3, FOTIVDA’s pivotal trial, was also presented during the conference. |
| 2024-07-18 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology, an LG Chem company, Announces Phase 3 Renal Cell Carcinoma Clinical Trial (TiNivo-2) Results aveooncology.com ↗
The addition of nivolumab to low dose tivozanib after prior immune checkpoint inhibitor (ICI) is not superior to standard dose tivozanib alone; as a result, the primary endpoint was not met |
| 2024-02-06 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist aveooncology.com ↗
In the publication, FOTIVDA demonstrated a consistent safety profile and a long-term survival benefit in patients who were alive and progression-free at 12 months, suggesting a durable clinical benefit and safety across age groups regardless of prior treatment. |
| 2022-06-06 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting aveooncology.com ↗
Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib |
| 2022-02-14 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma aveooncology.com ↗
We are excited to report that the five year follow-up data announced today show that patients receiving FOTIVDA are up to five times more likely to experience long-term progression free survival as compared to sorafenib. |
| 2022-01-20 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium aveooncology.com ↗
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC |
| 2021-05-19 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma aveooncology.com ↗
Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up |
| 2021-03-10 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA ® (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies. |
| 2021-02-11 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Presentation of Key Subgroup and Quality of Life Analyses from the Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma aveooncology.com ↗ |
| 2021-01-15 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma aveooncology.com ↗
The combination demonstrated a 29% partial response (PR) rate and 71% disease control rate (PR + stable disease). |
| 2020-11-05 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma aveooncology.com ↗
Additionally, the combination demonstrated anti-tumor activity and extended progression free survival (PFS), suggestive of the potential for favorable durability of response. |
| 2020-09-15 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. |
| 2020-08-10 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Oncology Reports Second Quarter 2020 Financial Results and Provides Business Update aveooncology.com ↗
NDA Filing Accepted by U.S. FDA for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma; Assigned PDUFA Target Action Date of March 31, 2021 |
| 2020-06-01 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (NASDAQ: AVEO) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC). |
| 2020-05-29 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured at ASCO 2020 Virtual Scientific Program and Submitted to U.S. FDA as Part of NDA Filing aveooncology.com ↗
AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured at ASCO 2020 Virtual Scientific Program and Submitted to U.S. FDA as Part of NDA Filing |
| 2020-05-29 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2 aveooncology.com ↗
The combination was well tolerated, with no dose limiting toxicities. |
| 2020-03-31 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC). |
| 2020-02-12 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Journal of Cancer aveooncology.com ↗
AVEO Oncology (NASDAQ: AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in patients with advanced, inoperable hepatocellular carcinoma (HCC) in the British Journal of Cancer. |
| 2019-12-04 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma aveooncology.com ↗ |
| 2019-11-18 | AVEO Pharmaceuticals, Inc. | Results AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (NASDAQ: AVEO) today announced the presentation of updated data from the Phase 3 TIVO-3 trial. |
| 2019-11-04 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma aveooncology.com ↗
The study also demonstrated a significant improvement in the secondary endpoint of overall response rate. |
| 2019-09-23 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma |
| 2019-09-10 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. |
| 2019-02-16 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Oral Presentation of TIVO-3 Trial Topline Results at the 2019 ASCO Genitourinary Cancers Symposium aveooncology.com ↗
This is underscored by a significant improvement in progression free survival and overall response rate compared to sorafenib in patients with treatment-refractory advanced RCC. |
| 2019-01-31 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Oncology Announces NDA Timing Update aveooncology.com ↗
The FDA indicated that these preliminary OS results do not allay their concerns about the potential detriment in OS outlined in the complete response letter dated June 6, 2013. |
| 2018-11-05 | AVEO Pharmaceuticals, Inc. | Results https://www.aveooncology.com/wp-content/uploads/2023/06/AVEO-Reports-Third-Quarter-2018-Financial-Results-and-Provides-Business-Update.pdf aveooncology.com ↗
Tivozanib demonstrated a 44% improvement in median PFS and 26% reduction in risk of progression or death (Hazard Ratio [HR]=0.74, p=0.02). |
| 2018-10-22 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology and EUSA Pharma Announce Updated Interim Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma aveooncology.com ↗
The combination was generally well tolerated. |
| 2018-03-21 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC aveooncology.com ↗
AVEO Oncology (NASDAQ: AVEO) today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib (FOTIVDA ® ) as second-line treatment in advanced renal cell carcinoma (aRCC), in the European Journal of Cancer. |
| 2018-02-12 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA® (tivozanib) as First Line Treatment for Advanced Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending FOTIVDA ® (tivozanib) for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC). |
| 2018-02-10 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology and EUSA Pharma Announce Encouraging Preliminary Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma aveooncology.com ↗
The combination was generally well tolerated. |
| 2018-01-19 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Presentation of Data from Phase 1b/2 Study of Tivozanib in Patients with Advanced Hepatocellular Carcinoma aveooncology.com ↗
AVEO Oncology Announces Presentation of Data from Phase 1b/2 Study of Tivozanib in Patients with Advanced Hepatocellular Carcinoma |
| 2017-11-06 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma aveooncology.com ↗
The combination was well tolerated to the full dose and schedule of single agent tivozanib, with no dose limiting toxicities. |
| 2017-10-05 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Completion of TIVO-3 Study Futility Analysis with No Changes to Study Protocol aveooncology.com ↗
Based on the results of the futility analysis, which was reviewed by an independent statistician, the study will continue as planned without modification. |
| 2017-08-28 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (NASDAQ: AVEO) today announced that the European Commission (EC) has approved FOTIVDA ® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) in the European Union plus Norway and Iceland. |
| 2017-06-23 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for approval as a treatment for patients with advanced renal cell carcinoma (RCC). |
| 2017-06-08 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in RCC Advances to Phase 2 aveooncology.com ↗
The combination was well tolerated to the full dose and schedule of single agent tivozanib, with no dose limiting toxicities. |
| 2017-04-13 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding Issues aveooncology.com ↗
AVEO Oncology (NASDAQ: AVEO) today announced that its European licensee for tivozanib, EUSA Pharma, has submitted responses to the European Medicines Agency (EMA) Day 180 List of Outstanding Issues (LOI) related to the Marketing Authorization Application (MAA) for tivozanib as a first-line treatment for renal cell carcinoma. |
| 2017-02-23 | AVEO Pharmaceuticals, Inc. | Results AVEO Announces TIVO-3 Passes The First Safety Monitoring Committee Safety Review aveooncology.com ↗
The SMC concluded that no safety concern was observed for tivozanib and recommended that the study replace the small number of patients who dropped out prior to starting treatment. |
| 2017-02-09 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Announces Clinical and Regulatory Updates for Tivozanib aveooncology.com ↗
Partner EUSA Pharma Receives Day 180 List of Outstanding Issues from EMA, Oral Explanation Expected in 2Q 2017 |
| 2016-11-28 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Tivozanib in Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (NASDAQ:AVEO) today announced that its development partner, EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, has submitted its responses to the European Medicines Agency (EMA) Day 120 List of Questions. |
| 2016-03-01 | AVEO Pharmaceuticals, Inc. | Regulatory EUSA Pharma and AVEO Announce Submission of Marketing Authorization Application for Tivozanib in Advanced Renal Cell Carcinoma aveooncology.com ↗
EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line treatment of advanced renal cell carcinoma (RCC). |
| 2016-02-22 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Announces Acceptance of Registration Dossier for Tivozanib in RCC by the Ministry of Health of the Russian Federation aveooncology.com ↗
AVEO Oncology (NASDAQ:AVEO) today announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal cell carcinoma (“RCC”) has been accepted by the Ministry of Health (“MoH”) of the Russian Federation. |
| 2015-06-03 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Announces Receipt of European Regulatory Guidance Regarding Potential Marketing Authorization Application for Tivozanib aveooncology.com ↗
AVEO Announces Receipt of European Regulatory Guidance Regarding Potential Marketing Authorization Application for Tivozanib |
| 2015-05-20 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma aveooncology.com ↗
Final results now show a median PFS in this setting of 11.0 months and median overall survival (OS) of 21.6 months, demonstrating the efficacy of tivozanib in a VEGF treatment refractory population. |
| 2015-03-06 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Reports Full Year 2014 Financial Results aveooncology.com ↗
Today, AVEO announced the presentation of final results, including a predefined biomarker analysis, from the BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer (CRC). |
| 2015-03-06 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib Compared to Bevacizumab in Low Serum NRP-1 Patients with Advanced CRC aveooncology.com ↗
AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib Compared to Bevacizumab in Low Serum NRP-1 Patients with Advanced CRC |
| 2015-01-08 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application to the European Medicines Agency aveooncology.com ↗
AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing Authorization under the Agency’s centralized procedure. |
| 2014-09-29 | AVEO Pharmaceuticals, Inc. | Results AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress aveooncology.com ↗
“We remain encouraged by clinical outcomes from these Phase 2 studies, as they suggest potential avenues for the development of tivozanib,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. |
| 2013-12-13 | AVEO Pharmaceuticals, Inc. | Results AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer aveooncology.com ↗
data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. |
| 2013-06-11 | Astellas Pharma Inc | Regulatory Complete Response Letter for Tivozanib New Drug Application in Renal Cell Carcinoma astellas.com ↗ |
| 2013-06-10 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma aveooncology.com ↗
AVEO Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma |
| 2013-05-02 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma aveooncology.com ↗
AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma |
| 2013-05-02 | Astellas Pharma Inc | Regulatory AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma astellas.com ↗ |
| 2013-02-27 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO and Astellas Announce FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma aveooncology.com ↗
today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the company’s New Drug Application (NDA) for tivozanib for the treatment of patients with advanced renal cell carcinoma (RCC) during the morning session of its meeting on May 2, 2013. |
| 2013-02-12 | AVEO Pharmaceuticals, Inc. | Results AVEO and Astellas Report Final Overall Survival Results from TIVO-1 aveooncology.com ↗
The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib. |
| 2013-02-12 | Astellas Pharma Inc | Results AVEO and Astellas Report Final Overall Survival Results from TIVO-1 astellas.com ↗
The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib. |
| 2012-11-28 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma aveooncology.com ↗
The FDA’s acceptance of the NDA triggers a $15 million milestone payment to AVEO under its development and commercialization agreement with Astellas. |
| 2012-11-28 | Astellas Pharma Inc | Regulatory AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma astellas.com ↗
AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma |
| 2012-10-01 | AVEO Pharmaceuticals, Inc. | Results AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer aveooncology.com ↗
In addition to detailed safety results, pharmacokinetic/pharmacodynamic data from TIVO-1 were also presented. |
| 2012-10-01 | Astellas Pharma Inc | Results AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer First Patient Enrolled in TAURUS Patient Preference Study astellas.com ↗
Results presented at the ESMO 2012 Congress (European Society for Medical Oncology) in Vienna, Austria show that patients treated with tivozanib experienced fewer Grade 3 and off-target adverse events (AEs), stayed on treatment longer, and required fewer dose reductions and interruptions compared with those treated with sorafenib. |
| 2012-09-28 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO and Astellas Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma aveooncology.com ↗
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC). |
| 2012-09-28 | Astellas Pharma Inc | Regulatory AVEO and Astellas Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma astellas.com ↗
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC). |
| 2012-05-16 | AVEO Pharmaceuticals, Inc. | Results AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC aveooncology.com ↗
TIVO-1 is the first superiority pivotal study in first-line advanced renal cell carcinoma (RCC) in which an investigational agent (tivozanib) has demonstrated statistically significant and clinically meaningful progression-free survival (PFS) superiority versus an approved targeted agent (sorafenib) in advanced RCC. |
| 2012-04-12 | AVEO Pharmaceuticals, Inc. | Results AVEO Announces Publication of Positive Tivozanib Phase 2 ClinicalTrial Results in Journal of Clinical Oncology aveooncology.com ↗ |
| 2012-01-03 | AVEO Pharmaceuticals, Inc. | Results AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial aveooncology.com ↗
tivozanib demonstrated a statistically significant improvement in PFS with a median PFS of 11.9 months compared to a median PFS of 9.1 months for sorafenib in the overall study population |
| 2011-06-02 | AVEO Pharmaceuticals, Inc. | Results Final Analysis from AVEO Pharmaceuticals’ Phase 2 Trial of Tivozanib in Patients with Advanced Renal Cell Carcinoma Presented at ASCO aveooncology.com ↗
Median PFS Was 11.7 Months among All Treated Patients and 14.8 Months among Those with Clear Cell RCC Who Had Undergone Nephrectomy |
| 2011-01-21 | AVEO Pharmaceuticals, Inc. | Results AVEO Pharmaceuticals’ Tivozanib Clinical Data Featured at 2011 ASCO Gastrointestinal Cancers Symposium aveooncology.com ↗
Results from this study, which were previously reported at the EORTC-NCI-AACR Symposium in Berlin in November 2010, showed the combination was tolerable and safe at the full recommended tivozanib dose (1.5 mg/day) and schedule and standard FOLFOX6 dose; and, partial responses in more than a third (35 percent) of patients evaluated (n=17) and disease control in 82 percent of patients. |
| 2010-12-10 | AVEO Pharmaceuticals, Inc. | Results AVEO’s Tivozanib in Combination with Paclitaxel Demonstrates Safety in Patients with Metastatic Breast Cancer; Data Presented at San Antonio Breast Cancer Symposium aveooncology.com ↗
The combination was considered safe at the full recommended tivozanib dose (1.5 mg/day) and standard paclitaxel dose, and demonstrated encouraging clinical activity in patients with metastatic breast cancer. |
| 2010-11-18 | AVEO Pharmaceuticals, Inc. | Results AVEO’s Tivozanib in Combination with FOLFOX6 Demonstrates Anti-tumor Activity and Safety in Advanced GI Cancers; Results Presented at EORTC-NCI-AACR Symposium aveooncology.com ↗
AVEO’s Tivozanib in Combination with FOLFOX6 Demonstrates Anti-tumor Activity and Safety in Advanced GI Cancers; Results Presented at EORTC-NCI-AACR Symposium |
| 2010-10-11 | AVEO Pharmaceuticals, Inc. | Results AVEO Pharmaceuticals’ Tivozanib Clinical Data Featured at ESMO aveooncology.com ↗
today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35 th European Society for Medical Oncology (ESMO) Congress in Milan, Italy. |
| 2010-10-01 | AVEO Pharmaceuticals, Inc. | Results AVEO Pharmaceuticals’ Tivozanib Featured at Ninth International Kidney Cancer Symposium aveooncology.com ↗
Data showed that the median PFS achieved by patients with advanced clear cell RCC who had undergone a prior nephrectomy was 14.8 months – comparing favorably to historical data from trials testing other currently ap |
| 2010-06-24 | AVEO Pharmaceuticals, Inc. | Regulatory AVEO Pharmaceuticals, Inc. Receives Orphan Medicinal Product Designation for Tivozanib for the Treatment of Renal Cell Carcinoma by the European Medicines Agency aveooncology.com ↗
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received orphan medicinal product designation for tivozanib (N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N’-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate), its oral, triple VEGF receptor inhibitor, for the treatment of renal cell carcinoma by the European Medicines Agency (EMA). |
| 2010-06-07 | AVEO Pharmaceuticals, Inc. | Results AVEO Pharmaceuticals’ Tivozanib Demonstrates Progression-Free Survival of 14.8 Months in Subgroup of Patients with Advanced Kidney Cancer; Extended Duration of Treatment Continues to Highlight Favorable Tolerability Profile aveooncology.com ↗
Off-target toxicities commonly associated with other targeted therapies, such as mucositis, fatigue and hand-foot syndrome, were notably low during treatment with tivozanib. |
| 2009-11-17 | AVEO Pharmaceuticals, Inc. | Results AVEO’s Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting aveooncology.com ↗
Preliminary results of this ongoing study show tumor shrinkage in 12 out of 16 patients evaluated, and two partial responses as assessed by RECIST criteria; the combination was well-tolerated with no dose limiting toxicities (DLT). |
| 2009-07-31 | AVEO Pharmaceuticals, Inc. | Results AVEO’s Tivozanib Demonstrates Anti-Tumor Activity in Engineered Lung Tumors Exhibiting Treatment Resistant Mutations aveooncology.com ↗
Specifically, treatment with tivozanib resulted in complete tumor growth inhibition or tumor regression (shrinkage) in lung tumors driven by EGFR or KRAS mutations, which are especially difficult to treat. |
| 2009-05-29 | AVEO Pharmaceuticals, Inc. | Results AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer; Phase 2 Data Presented at ASCO aveooncology.com ↗
The median progression-free survival (PFS) achieved by patients in this Phase 2 trial (N=272) was 11.8 months. |
| 2009-04-21 | AVEO Pharmaceuticals, Inc. | Results AVEO Announces Positive Finding for Triple VEGF Receptor Inhibitor AV-951 aveooncology.com ↗
The activity of AV-951 in AVEO-engineered models of hepatocellular carcinoma highlights the potential role of our novel, triple VEGF receptor inhibitor in the treatment of this deadly cancer. |
| 2009-02-25 | AVEO Pharmaceuticals, Inc. | Results AVEO Pharmaceuticals’ Oral, Triple VEGF Receptor Inhibitor AV-951 Shows Robust Activity in Patients with Advanced Kidney Cancer aveooncology.com ↗
As assessed by independent radiological review, patients with advanced RCC treated with AV-951 experienced a 91.7 percent disease control rate at 16 weeks. |
| 2008-04-14 | AVEO Pharmaceuticals, Inc. | Results AVEO Pharmaceuticals’ Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal Cancer; Clinical Activity and Tolerability in other Solid Tumors including Colon and Lung Cancers aveooncology.com ↗
Partial response or stable disease was observed across all patients with renal cell carcinoma, and overall, one-third of patients across all tumor types achieved tumor shrinkage during treatment with AV-951. |
| 2007-11-06 | AVEO Pharmaceuticals, Inc. | Results Results from Phase 1 Study of AVEO’s Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease aveooncology.com ↗
Notably, of the nine patients with refractory renal cell carcinoma, all achieved either a partial response or stable disease as defined by the trial protocol, with one patient exhibiting a response lasting more than 30 months. |
All press releases naming this drug 146 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 146 releases opens the full record — a long page | ||
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 42 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tivozanib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00502307 ↗ |
| Known as | (tivozanib hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289494 ↗ |
| Known as | ASP-4130 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289494 ↗ |
| Known as | AV-951 | “Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks).” NCT00717340 ↗8“This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in treating patients with recurrent or metastatic renal cell cancer.” NCT00502307 ↗ “The purpose of this study is to test the safety and tolerability of tivozanib (AV-951) and Torisel™ given in combination for renal cell cancer.” NCT00563147 ↗ “Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off.” NCT01369433 ↗ “Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers” NCT04645160 ↗ “Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily” NCT00660153 ↗ “Drug: Tivozanib (AV-951)” NCT00826878 ↗ “Drug: tivozanib (AV-951)” NCT01030783 ↗ “tivozanib (AV-951)” NCT01306630 ↗ |
| Known as | DC-001164TIVOZANIBAV9511-(2-CHLORO-4((6,7-DIMETHOXYQUINOLIN-4-YL)OXY)PHENYL)-3-(5-METHYLISOXAZO-3-YL)UREA | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289494 ↗ |
| Known as | FOTIVDA | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289494 ↗ |
| Known as | KIL-8951 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289494 ↗ |
| Known as | KRN951 | “Tivozanib hydrochloride (tivozanib; previously known as AV-951 and as KRN951) has the chemical name” NCT03136627 ↗ |
| Known as | OPHTHOTECH | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289494 ↗ |
| Known as | TIVOZANIB (AV-951) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289494 ↗ |
| Known as | TIVOZANIB (OPHTHALMIC) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289494 ↗ |
| Known as | TIVOZANIB HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289494 ↗ |
| Known as | tivozanib hydrochloride | “Tivozanib hydrochloride (tivozanib) is a potent and selective tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors with antitumor activity additive...” PMID 25591799 ↗ Dec 20142“Tivozanib hydrochloride (tivozanib; previously known as AV-951 and as KRN951) has the chemical name” NCT03136627 ↗ “Participants randomized to this arm will receive the study drug, tivozanib hydrochloride.” NCT02627963 ↗ |
| Known as | Tivozanib hydrochloride monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289494 ↗ |
| Action | Inhibit | “Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor.” NCT00502307 ↗2“Platelet-derived growth factor receptor beta inhibitor” CHEMBL1289494 ↗ “Stem cell growth factor receptor inhibitor” CHEMBL1289494 ↗ |
| Modality | Small molecule | “Tivozanib is a potent small molecule tyrosine kinase inhibitor against VEGFR1-3” PMID 27771610 ↗ Jan 2017 |
| Route | Oral | “solid oral dosage form taken daily for three weeks per one month cycle” NCT00502307 ↗ |
| Target | KIT | “Stem cell growth factor receptor inhibitor” CHEMBL1289494 ↗ |
| Target | PDGFRB | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL1289494 ↗ |